Pembrolizumab in Patients With Leptomeningeal Disease
Status:
Terminated
Trial end date:
2019-12-14
Target enrollment:
Participant gender:
Summary
This is an open-label phase II study of pembrolizumab in patients with advanced solid tumors
with leptomeningeal carcinomatosis (LMD). Approximately 18 subjects in this study will
receive pembrolizumab at a dose of 200mg intravenously (IV) every 3 weeks (Q3W) for 4 doses.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins